

## Pharmacogenetic Gene Analysis and Testing Platform Brings Cost-Effective Genetic Profiling and Precision Medicine to Healthcare Organizations and Hospitals



Ulrich Broeckel, MD  
Founder and Chief Executive Officer

RPRD Diagnostics LLC  
[www.rprdx.com](http://www.rprdx.com)

Contact:  
Ulrich Broeckel, MD,  
CEO and Founder, RPRDx  
414-316-3101  
[ubroeckel@rprdx.com](mailto:ubroeckel@rprdx.com)

Interview conducted by:  
Lynn Fosse, Senior Editor  
CEOCFO Magazine

**CEOCFO: Dr. Broeckel, tell us the vision behind RPRDx?**

**Dr. Broeckel:** The concept and idea behind Right Person Right Drug Diagnostics (RPRDx) is to bring pharmacogenetics testing, which analyzes patients' genomes for variations that are known to impact drug safety and efficacy, to patients, healthcare organizations and hospitals. Bringing a cost-effective genetic screening service such as ours into routine clinical practice will enable health care providers to tailor drug prescriptions to individual patients.

**CEOCFO: What is your approach?**

**Dr. Broeckel:** Over the past decade, there have been major advances in pharmacogenetics, improving our understanding of how genetics contribute to an individual's response to a drug. Unfortunately, these advances have not been widely implemented due to the high cost and narrow scope of currently available tests. There are a number of companies who work in this field using various, but limited, approaches that screen a subset of genes at a time. RPRDx offers pharmacogenetics testing services that survey thousands of clinically actionable gene variants in parallel and provides the necessary interpretation and integration into the client's electronic medical record (EMR) systems to become part of the patient's record. Tailoring treatments per known pharmacogenetic reactions can improve patient outcomes, reduce the risk of adverse drug reactions, and lower overall costs.

RPRDx is a spinoff from the Medical College of Wisconsin in Milwaukee, and for many years we have been implementing pharmacogenetics in clinical practice. RPRDx is building upon this experience but also on significant advances in genotyping and pharmacogenetic analysis technology. We are launching our company with the most comprehensive and cost-effective technology platform available to analyze pharmacogenetic genes, called Pharmacoscan™, which we developed together with ThermoFisher Scientific (Affymetrix at that time).

**CEOCFO: What are you able to analyze that perhaps others cannot do as well?**

**Dr. Broeckel:** RPRD Diagnostics' unique services enable health care providers to preemptively screen a patient's DNA for almost all variations known to impact the performance or metabolism of a drug, and we do so at a very competitive price. In addition, we also have the expertise to help hospitals and healthcare organizations implement this large set of data in their EMR systems and interpret it.